Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice
Autor: | James T. Boothe, Odeth O. Barrett-Campbell, Andres E. Mindiola-Romero, Chaofan Yuan, Landis R. Walsh, Swaroopa Yerrabothala, Frederick Lansigan, Heather E. Conway |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Daunorubicin medicine.medical_treatment Gastroenterology Article 03 medical and health sciences 0302 clinical medicine Cholestasis Internal medicine hemic and lymphatic diseases Medicine Hydroxyurea Chemotherapy Extramedullary manifestation of AML Cytoreductive therapy RC254-282 Acute myeloid leukemia business.industry fungi food and beverages Myeloid leukemia Neoplasms. Tumors. Oncology. Including cancer and carcinogens Hematology medicine.disease Oncology 030220 oncology & carcinogenesis Toxicity Cholecystitis Cytarabine Liver function business 030215 immunology medicine.drug |
Zdroj: | Leukemia Research Reports, Vol 15, Iss, Pp 100251-(2021) Leukemia Research Reports |
ISSN: | 2213-0489 |
Popis: | Highlights • Acute myeloid leukemia can present as cholestasis with obstructive jaundice. • Extramedullary leukemia infiltration of liver can delay initiation of chemotherapy. • Hydroxyurea may be employed as a temporizing measure for effects of hyperleukocytosis. We present the case of a 55-year-old woman who presented with laboratory studies concerning for acute myeloid leukemia (AML) as well as obstructive cholestasis. In similar previously reported cases, concerns of chemotherapy toxicity exacerbated by liver dysfunction or concerns of untreated, concurrent cholecystitis in a neutropenic patient often delay initiation of chemotherapy for full medical workup. At admission, our patient was started on the cytoreductive agent hydroxyurea. By day 10 of her medical workup, her liver function had improved with total bilirubin levels normalizing. At that time, full-dose 7 + 3 induction with cytarabine and daunorubicin was then initiated. |
Databáze: | OpenAIRE |
Externí odkaz: |